Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03374475 Not yet recruiting - Clinical trials for Depressive Disorder, Major

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Start date: December 18, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 [HDRS17], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 [HAM-D6]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale [RRS], Sleep and Worry visual analogue scale [VAS], quantitative electro-encephalography [qEEG], heart rate variability [HRV] and others).

NCT ID: NCT03367533 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Start date: January 2018
Phase: Phase 1
Study type: Interventional

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

NCT ID: NCT03360695 Not yet recruiting - Breast Cancer Clinical Trials

BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

Start date: December 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.

NCT ID: NCT03357796 Recruiting - Clinical trials for Major Depressive Disorder

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Start date: November 27, 2017
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.

NCT ID: NCT03353493 Recruiting - Clinical trials for Major Depressive Disorder, Recurrent

Neural Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder

Start date: February 15, 2017
Phase: N/A
Study type: Interventional

The primary purpose of this study is to investigate neural mechanisms and predictors of treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major Depressive Disorder.

NCT ID: NCT03352453 Not yet recruiting - Clinical trials for Depressive Disorder, Major

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

NCT ID: NCT03347487 Recruiting - Clinical trials for Treatment Resistant Major Depression Disorder

Deep Brain Stimulation of the Bilateral Habeluna for Treatment- Resistant Major Depression

Start date: November 13, 2017
Phase: N/A
Study type: Interventional

Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) in treatment-resistant depression (TRD). However, the results of placebo-controlled trials have been mixed. Here the investigators will explore whether active DBS in habeluna for TRD will result in better symptom improvement than sham DBS. This study will also use structural and functional MRI to identify the brain network changes between pre-operative, post operative active DBS and shame DBS.

NCT ID: NCT03336918 Recruiting - Depression Clinical Trials

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

Start date: December 7, 2017
Phase: N/A
Study type: Observational

Lithium is highly effective in the treatment of bipolar disorder. This study aims to investigate, for the first time, the impact of lithium monotherapy on the structural and functional connectivity of the brain using MRI imaging.

NCT ID: NCT03329287 Recruiting - Clinical trials for Major Depressive Disorder

Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

This trial attempts to evaluate the treatment efficacy of Simplified Cognitive Behavioral Therapy (SCBT) and its safety among schizophrenia patients. Half of participants will be randomized to accept SCBT.

NCT ID: NCT03328819 Recruiting - Depression Clinical Trials

Therapeutic Effect and Mechanism of Acupuncture Treating Chronic Pain and Major Depression Comorbidity

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Objectives: The effect of acupuncture as treatment for chronic pain and depression comorbidity is questionable because only a limited number of controlled clinical trials with sound methodologies have been conducted. The investigators will perform a well-designed crossover study including assessments of scales and blood sample analysis to investigate the efficacy of acupuncture as treatment for comorbidity of chronic pain and major depression disorder (MDD) and figure out the indicative biomarkers to predict or assess the comorbidity. Methods: Patients with a recent major depression and chronic pain were randomized to receive acupuncture for depression group or acupuncture for chronic pain. They will receive 2~3 sessions per week over 6 consecutive weeks. Then patients accept another 6weeks sessions after two-week washout. During washout period, original western treatment will be maintained and acupuncture will be interrupted. The primary outcome measure was change in 21-item Hamilton Depression Rating Scale (HAMD), pain with Brief Pain Inventory- Long form (BPI). Secondary outcome measures included changes in Beck Depression Inventory-II (BDI-II), Neurotoxicity Rating Scale (NTRS), WHO Quality of Life (WHOQoL), Clinical Global Impression (CGI), biomarkers such as neurotransmitter, kinase, protein, cytokine, DNA, mRNA related to comorbidity of chronic pain and major depression.